Nontuberculous Mycobacterial Lung Disease

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advertisements

Moderate-to-Severe Asthma Management

Chronic HCV Infection and CKD

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Systemic Lupus Erythematosus

Clinical Trials in IBD.

The Effect of Intra-Articular Steroids on Cartilage in Knee Osteoarthritis.

New Psoriasis Treatments

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Improving Survival in Glioblastoma Multiforme

Advances in Managing Inhibitors in Patients With Hemophilia A

Exploring the Spectrum of Excessive Daytime Sleepiness

Progression After Cancer Immunotherapy in Advanced NSCLC

Understanding the Many Faces of Pseudobulbar Affect

Ask the Onychomycosis Expert, Part 2

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples.

New Standards of Care in ALK-Translocated Advanced NSCLC

Improving Acne Outcomes

Case Challenges in Chronic Migraine

Updates in Management of Atopic Dermatitis From Real Patient Cases

Before and After: Patient Cases in Onychomycosis

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Chronic Idiopathic Urticaria

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Addressing Disease Burden in Asthma

Asthma and Atopic Comorbidities

The Evolving Role of Immunotherapy in NSCLC

Multidisciplinary Perspectives on Interstitial Lung Diseases

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Hyperhidrosis Is Burdensome!

Gene Therapy: Past, Present, and Future

Diagnosing Nontuberculous Mycobacterial Disease

Immunotherapy for cSCC

Advancing the Treatment of IBD With Biologics

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

New Recommendations on How to Stage Hidradenitis Suppurativa

When Is Biologic Therapy Appropriate for HS?

How to Select Therapy In Newly Diagnosed CLL

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Parkinson Disease Psychosis

Talking With Your Patients About Excessive Sweating

Guide to Atopic Dermatitis

Chronic Myeloid Leukemia Challenge

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Burden of Psoriasis:

Patient Questions and Expert Answers in Psoriasis:

Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination M.-R. Lee,

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

The Psychiatrist's Role in Tardive Dyskinesia

Pregnancy in MS.

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

The Psychiatrist's Role in Tardive Dyskinesia

HAE Prophylaxis.

Checkpoint Inhibitors in First-Line Advanced NSCLC

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Balancing the Risks and Benefits of Multidrug Regimens in the Clinical Management of Nontuberculous Mycobacterial Lung Disease.

Immune Checkpoint Inhibitors in Lung Cancer

Management of NTM Lung Disease

Presentation transcript:

Nontuberculous Mycobacterial Lung Disease

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Burden of NTM Lung Disease

Classification of NTM Pathogens by Growth Rate

US Regional Differences in NTM Lung Disease

Identifying NTM and Underlying Disease

Clinical Criteria for Diagnosis of NTM Lung Disease

Microbiologic Criteria for Diagnosis of NTM Lung Disease

Tracking Disease Progression: 3-Point Follow-up

Radiologic Patterns of NTM Lung Disease

Focal Bronchiectasis

Tree-in-Bud Appearance

Nodular Bronchiectasis

Cavitary Disease

M avium Complex

Which Patients Require Therapy?

Identification of NTM

Susceptibility Testing

Challenges to Successful Diagnosis and Treatment of NTM

Treatment and Management of Macrolide-Susceptible NTM Lung Disease

M abscessus

M kansasii

How to Determine if Treatment Is Successful

Drug Toxicities: What To Watch For

What if Your Patient Shows No Improvement?

Emerging Therapies for NTM Lung Disease

Summary

Abbreviations

Abbreviations (cont)